ISPOR - Cost-Effectiveness Analysis of Omalizumab Compared With Standard of Care For Severe Allergic Asthma Based On Real World Evidence in Japan

Full Text

Cost-Effectiveness Analysis of Omalizumab Compared With Standard of Care For Severe Allergic Asthma Based On Real World Evidence in Japan

Abstract

Authors

M Muthukumar M Kozawa L Alvares K Milligan A Igarashi

Back to Volume 21, Supplemental S2

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now